Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COV01
- Development stage
- Preclinical
- Lead developer
- Nanjing University
- Modality
- Small Molecules
01
Overview
COV01 is a small molecule inducer of extra-renal 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) expression. It is being developed for the treatment of age-related muscle loss (sarcopenia). By upregulating CYP27B1 expression in muscle tissue, COV01 promotes myotube formation, enhances mitochondrial biogenesis, and improves muscle strength. When combined with 25-hydroxyvitamin D3 (25(OH)D3), COV01 exhibits a synergistic effect, further enhancing mitochondrial biogenesis and myotube formation, making it a potential therapeutic candidate for the clinical management of sarcopenia.
Beyond the preview
Go deeper on COV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COV01.